| Identification | Back Directory | [Name]
7-[3,5-Difluoro-4-(4-morpholinylmethyl)phenyl]-N-[4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-2-amine | [CAS]
1414587-22-6 | [Synonyms]
| [Molecular Formula]
C29H33F2N7O | [MOL File]
1414587-22-6.mol | [Molecular Weight]
533.62 |
| Hazard Information | Back Directory | [Uses]
BVB808 (NVP_BVB808) is a selective JAK2 inhibitor with approximately 10-fold selectivity for JAK2 over other JAK family members (such as JAK1, JAK3 or TYK2) in vitro. BVB808 inhibits the activity of JAK2 and reduces the phosphorylation of STAT5, thereby blocking the JAK2-dependent cell proliferation and survival signaling pathways. BVB808 can be used in cancer research[1]. | [References]
[1] Weigert, et al. "Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition." The Journal of experimental medicine 209.2 (2012): 259. DOI:10.1084/jem.20111694 |
|
|